| Not Yet Recruiting | Phase 2b of RAPA-201 Cell Therapy in Post-PD-(L)-1 Melanoma NCT06708455 | Rapa Therapeutics LLC | Phase 2 |
| Recruiting | An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors NCT07371663 | Beijing Tide Pharmaceutical Co., Ltd | Phase 1 / Phase 2 |
| Recruiting | Reducing Symptom Burden Through Physical Exercise in Melanoma Patients NCT06985056 | Universität Duisburg-Essen | N/A |
| Not Yet Recruiting | Immune PET and Proteomics for the Assessment of Response to Spatially Fractionated or Palliative Radiotherapy NCT06976021 | Maria Sklodowska-Curie National Research Institute of Oncology | Phase 2 |
| Recruiting | A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/I NCT06961006 | Merck Sharp & Dohme LLC | Phase 2 |
| Active Not Recruiting | A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies NCT06974734 | Pfizer | Phase 1 |
| Recruiting | Video-Tumorboard PLUS NCT06980740 | University Hospital Muenster | — |
| Terminated | A Study to Learn About the Study Medicine Called PF-08046031 in Advanced Melanoma and Other Solid Tumors NCT06799533 | Pfizer | Phase 1 |
| Recruiting | Preoperative Planning With PSMA-PET in Melanoma Surgery Trial NCT06560905 | Royal Marsden NHS Foundation Trust | Phase 2 |
| Not Yet Recruiting | A Single-arm, Multicenter Clinical Study of Fruquintinib Combined With Cadonilimab Injection and Temozolomide NCT06553781 | Fudan University | N/A |
| Suspended | T3011 in Combination With Cobimetinib in Patients With Advanced Melanoma NCT05756556 | ImmVira Pharma Co. Ltd | Phase 2 |
| Recruiting | Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezo NCT06332755 | LG Chem | Phase 1 |
| Completed | IFN-Gamma Expression as a Predictor of Response to Immune Checkpoint Inhibitors in First-Line Metastatic Melan NCT07436390 | Institute of Oncology Ljubljana | N/A |
| Recruiting | A Phase 1 of CTX-8371 in Patients With Advanced Malignancies NCT06150664 | Compass Therapeutics | Phase 1 |
| Recruiting | GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Sol NCT06265025 | GeneMedicine Co., Ltd. | Phase 1 / Phase 2 |
| Completed | Improved Early Diagnosis in Female Pelvic Cancer With OC Detect NCT06613230 | Region Skane | — |
| Recruiting | AMT-253 in Patients With Advanced Solid Tumours NCT06209580 | Multitude Therapeutics Inc. | Phase 1 / Phase 2 |
| Recruiting | FMT in Checkpoint Inhibitor-mediated Diarrhea and Colitis NCT06206707 | University of Aarhus | N/A |
| Terminated | Study of IK-595 in RAS- or RAF-altered Advanced Tumors NCT06270082 | Ikena Oncology | Phase 1 |
| Completed | Retinal Structural and Functional Changes in Patients Treated With BRAF/MEK Inhibitors NCT07431489 | Institute of Oncology Ljubljana | N/A |
| Completed | Overcoming Primary Resistance to Immunotherapy in Metastatic Melanoma NCT05304546 | Dr. Ronnie Shapira | Phase 2 |
| Terminated | A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and NCT05551117 | MacroGenics | Phase 2 |
| Unknown | Recombinant Human Adenovirus Type 5 Injection Combined With PD-1 Monoclonal Antibody and Nab-paclitaxel in the NCT05664139 | Fujian Cancer Hospital | Phase 2 |
| Completed | Clinical and Functional Retinal Changes Associated With BRAF/MEK Inhibitor Therapy in Patients With Malignant NCT07427953 | Institute of Oncology Ljubljana | — |
| Recruiting | GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2 NCT05130255 | Y-mAbs Therapeutics | Phase 1 |
| Active Not Recruiting | Binimetinib Encorafenib Pembrolizumab +/- Stereotactic Radiosurgery in BRAFV600 Melanoma With Brain Metastasis NCT04074096 | UNICANCER | Phase 2 |
| Active Not Recruiting | Oral Decitabine/Cedazuridine (DEC-C) in Combination With Nivolumab for Patients With Mucosal Melanoma NCT05089370 | University of Colorado, Denver | Phase 1 / Phase 2 |
| Completed | Diagnostic Precision of the AI Tool Dermalyzer to Identify Malignant Melanomas in Subjects Seeking Primary Car NCT05172232 | Linkoeping University | — |
| Completed | Fast Track Diagnosis of Skin Cancer by Advanced Imaging Technologies and Tumour Tapestripping NCT05389085 | University Hospital Bispebjerg and Frederiksberg | N/A |
| Completed | A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors NCT05293496 | MacroGenics | Phase 1 |
| Unknown | Shared Decision Making in Melanoma Patients Receiving Adjuvant Therapy NCT06294379 | Odense University Hospital | — |
| Recruiting | The Gut Microbiome and Immune Checkpoint Inhibitor Therapy in Solid Tumors NCT05037825 | VastBiome | — |
| Completed | Observational Study for Melanoma Adjuvant Treatment With Tafinlar® + Mekinist® (Dabrafenib + Trametinib) NCT04547946 | Novartis Pharmaceuticals | — |
| Terminated | ImmPACT Expanded Multiple Antigen Specific Endogenously Derived T Cells (MASE-T) to Patients With Metastatic M NCT04904185 | Inge Marie Svane | Phase 1 |
| Recruiting | RAPA-201 Therapy of Solid Tumors NCT05144698 | Rapa Therapeutics LLC | Phase 1 / Phase 2 |
| Terminated | A Study of SAR444245 Combined With Cemiplimab for the Treatment of Participants With Various Advanced Skin Can NCT04913220 | Sanofi | Phase 1 / Phase 2 |
| Terminated | L-TIL Plus Tislelizumab as First-line Treatment in Advanced Malignant Melanoma NCT04924413 | Quanli Gao | Phase 2 |
| Unknown | First in Human Study of NVG-111 in Relapsed/Refractory ROR1+ Malignancies NCT04763083 | NovalGen Ltd. | Phase 1 |
| Recruiting | Toripalimab Combined With Radiotherapy and Chemotherapy in the Treatment of SNMM After Endoscopic Surgery NCT04879654 | Eye & ENT Hospital of Fudan University | Phase 2 |
| Unknown | A Study of Toripalimab or Combining With Temozolomide（iv） in the Treatment of Advanced/Metastatic Malignant Me NCT04884997 | First Affiliated Hospital of Zhejiang University | Phase 2 |
| Withdrawn | ECT-Pembrolizumab in Patients With Unresectable Melanoma With Superficial or Superficial and Visceral Metastas NCT03448666 | European Institute of Oncology | Phase 2 |
| Terminated | A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involveme NCT04543188 | Pfizer | Phase 1 |
| Recruiting | Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignanc NCT04282044 | BioEclipse Therapeutics | Phase 1 |
| Withdrawn | Prevention of Recurrence and Metastasis in Genetically High-Risk Melanomas NCT04285749 | Case Comprehensive Cancer Center | EARLY_Phase 1 |
| Unknown | Anti-PD-1 Antibody in the Treatment of Patients With Malignant Melanoma of the Female Genital Tract NCT04593485 | Fudan University | Phase 2 |
| Completed | A Study of the Safety and Tolerance of CAN04 and Pembrolizumab in Combination With and Without Carboplatin and NCT04452214 | Cantargia AB | Phase 1 |
| Recruiting | Carbon Ion Radiation Therapy in the Treatment of Mucous Melanomas of the Female Lower Genital Tract NCT05478876 | CNAO National Center of Oncological Hadrontherapy | N/A |
| Withdrawn | Programmed Cell Death 1 + Selected Cell Therapy With Durvalumab (MEDI4736) and Tremelimumab in Metastatic Mela NCT04223648 | Yale University | EARLY_Phase 1 |
| Completed | Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line In NCT04889118 | Merck Sharp & Dohme LLC | Phase 3 |
| Recruiting | A Phase I, First in Human Study of CBA-1205, Anti-DLK1 Monoclonal Antibody in Patients With Advanced Solid Tum NCT06636435 | Chiome Bioscience Inc. | Phase 1 |
| Completed | UV1 Vaccination Plus Nivolumab and Ipilimumab in Treatment of Melanoma NCT04382664 | Ultimovacs ASA | Phase 2 |
| Completed | Pre Transplantation Melanoma NCT04217382 | Hospices Civils de Lyon | — |
| Completed | A Phase I/II Trial Investigating LOAd703 in Combination With Atezolizumab in Malignant Melanoma NCT04123470 | Lokon Pharma AB | Phase 1 / Phase 2 |
| Recruiting | A Randomized Controlled Phase II Trial With Intradermal IMO-2125 in Pathological Tumor Stage (p) T3-4 cN0M0 Me NCT04126876 | A.J.M. van den Eertwegh | Phase 2 |
| Completed | Boron Neutron Capture Therapy Using CICS-1 and SPM-011 for Malignant Melanoma and Angiosarcoma NCT04293289 | Cancer Intelligence Care Systems, Inc. | N/A |
| Completed | Fast Track Diagnosis of Skin Cancer by Advanced Imaging NCT04229277 | University Hospital Bispebjerg and Frederiksberg | N/A |
| Active Not Recruiting | SCIB1 and iSCIB1+ in Melanoma Patients Receiving Nivolumab With Ipilimumab or SCIB1 With Pembrolizumab (The SC NCT04079166 | Scancell Ltd | Phase 2 |
| Unknown | This Study is a Phase II Study of AZD6738 in Combination With Durvalumab in Patients With Solid Tumor (Cohort NCT03780608 | Samsung Medical Center | Phase 2 |
| Completed | Neurofilament Light Protein in Peripheral Blood Used as a Biomarker for Neurotoxicity After Isolated Limb Perf NCT04460053 | Vastra Gotaland Region | N/A |
| Completed | Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line In NCT03820986 | Merck Sharp & Dohme LLC | Phase 3 |
| Unknown | Tinostamustine and Nivolumab in Advanced Melanoma NCT03903458 | Markus Joerger | Phase 1 |
| Completed | Arginase-1 Peptide Vaccine in Patients With Metastatic Solid Tumors NCT03689192 | Herlev Hospital | Phase 1 |
| Unknown | Treatment of Malignant Melanoma With GPA-TriMAR-T Cell Therapy NCT03649529 | Timmune Biotech Inc. | EARLY_Phase 1 |
| Completed | High Intensity Interval Training (HIIT) for Patients With Cancer-related Lymphedema in the Lower Limbs NCT03653819 | Herlev and Gentofte Hospital | N/A |
| Completed | Study of Dabrafenib+Trametinib in the Adjuvant Treatment of Stage III BRAF V600+ Melanoma After Complete Resec NCT03551626 | Novartis Pharmaceuticals | Phase 3 |
| Completed | Phase Ib of L-NMMA and Pembrolizumab NCT03236935 | The Methodist Hospital Research Institute | Phase 1 |
| Completed | Test of Interventions to Prevent Skin Cancer Among Danes on Vacation in High UV Index Sunny Destinations NCT03607578 | Brian Køster | N/A |
| Completed | UV1 Vaccine With Pembrolizumab for Patients With Unresectable or Metastatic Melanoma NCT03538314 | Ultimovacs ASA | Phase 1 |
| Terminated | E6201 Plus Dabrafenib for the Treatment of Metastatic Melanoma Central Nervous System Metastases (CNS) NCT03332589 | Spirita Oncology, LLC | Phase 1 |
| Recruiting | Melanoma Metastasized to the Brain and Steroids NCT03563729 | Inge Marie Svane | Phase 2 |
| Unknown | Real World Study of Four PD-1 Agents in China NCT03966456 | The Affiliated Hospital of Qingdao University | — |
| Completed | Encorafenib + Binimetinib + Pembrolizumab in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanom NCT02902042 | Prof. Dr. med. Dirk Schadendorf | Phase 1 / Phase 2 |
| Completed | PET Imaging of the Immune System Using Analog Probes NCT03409419 | Jonsson Comprehensive Cancer Center | — |
| Completed | Suction Drain in Axillary Lymph Node Dissection for Malignant Melanoma NCT04648163 | Medical University of Graz | — |
| Unknown | Clinical Study of Apatinib as the Second-line Therapy in Malignant Melanoma NCT03383237 | Henan Cancer Hospital | Phase 2 |
| Completed | 4SC-202 in Combination With Pembrolizumab in Patients Primary Refractory/Non-responding to Prior Anti-PD-1 The NCT03278665 | 4SC AG | Phase 1 / Phase 2 |
| Completed | Lymph Node Identification in Skin Malignancy Using ICG Transcutaneously Study NCT03545334 | Insel Gruppe AG, University Hospital Bern | N/A |
| Completed | Co-stimulatory Markers and Vitamin D Status in Anti-PD1 Treated Melanoma Patients NCT03197636 | Aarhus University Hospital | — |
| Completed | The ACTIVATE (Adoptive Cell Therapy InVigorated to Augment Tumor Eradication) Trial NCT03158935 | University Health Network, Toronto | Phase 1 |
| Completed | Cobimetinib (Targeted Therapy) Plus Atezolizumab (Immunotherapy) in Participants With Advanced Melanoma Whose NCT03178851 | Hoffmann-La Roche | Phase 1 |
| Recruiting | A Randomized Trial to Assess the Role of Imaging During Follow Up After Radical Surgery of High Risk Melanoma NCT03116412 | Uppsala University | N/A |
| Completed | Phase 1B Study Evaluating Alternative Routes of Administration of CMP-001 in Combination With Pembrolizumab in NCT03084640 | Regeneron Pharmaceuticals | Phase 1 |
| Completed | Study of 1cm Versus 2cm Margins for the Surgical Treatment of cT2N0M0 Melanoma NCT03034395 | University of Kansas Medical Center | N/A |
| Terminated | IMCgp100-401 Rollover Study NCT02889861 | Immunocore Ltd | Phase 2 |
| Completed | Melanoma Image Analysis Algorithm (MIAA) Validation Study NCT02612168 | Skin Analytics Limited | N/A |
| Withdrawn | A Trial of CDX-1401 in Combination With Poly-ICLC and Pembrolizumab, in Previously Treated Advanced Solid Tumo NCT02661100 | Case Comprehensive Cancer Center | Phase 1 / Phase 2 |
| Terminated | Autologous T Cells Expressing MET scFv CAR (RNA CART-cMET) NCT03060356 | University of Pennsylvania | EARLY_Phase 1 |
| Unknown | Definition of an Immune Signature Predictive of Anti-PD1 (Programmed Death-1) Antibody in the Treatment of Adv NCT02938728 | Assistance Publique - Hôpitaux de Paris | — |
| Completed | Evaluating the Efficacy and Safety of a Sequencing Schedule of Cobimetinib Plus Vemurafenib Followed by Immuno NCT02902029 | University Hospital, Essen | Phase 2 |
| Completed | A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer NCT02897765 | BioNTech US Inc. | Phase 1 |
| Completed | Selective HDAC6 Inhibitor ACY-241 in Combination With Ipilimumab and Nivolumab NCT02935790 | Celgene | Phase 1 |
| Terminated | Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors NCT02709889 | AbbVie | Phase 1 / Phase 2 |
| Active Not Recruiting | Neoadjuvant L19IL2/L19TNF- Pivotal Study NCT02938299 | Philogen S.p.A. | Phase 3 |
| Active Not Recruiting | Study of the Effects of Pembrolizumab in Patients With Advanced Solid Tumors NCT02644369 | University Health Network, Toronto | Phase 2 |
| Completed | Vemurafenib and Cobimetinib Combination in BRAF Mutated Melanoma With Brain Metastasis NCT02537600 | Center Eugene Marquis | Phase 2 |
| Terminated | ImmuniCell® in Patients With Advanced Cancers NCT02459067 | TC Biopharm | Phase 2 |
| Terminated | Biopsy- and Biology-driven Optimization of Targeted Therapy in Subjects With Advanced Melanoma NCT02410863 | Prof. Dr. med. Dirk Schadendorf | Phase 2 |
| Withdrawn | Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Advanced Cutaneous Mela NCT02535078 | Immunocore Ltd | Phase 1 / Phase 2 |
| Completed | Pilot Study of Vigil™ + Pembrolizumab for Advanced Melanoma NCT02574533 | Gradalis, Inc. | Phase 1 |
| Completed | PLX3397 KIT in Acral aNd mucOsal Melanoma NCT02071940 | The Christie NHS Foundation Trust | Phase 2 |
| Terminated | Immunostimulating Interstitial Laser Thermotherapy in Malignant Melanoma NCT02650492 | Clinical Laserthermia Systems AB | N/A |
| Completed | Immunotherapy With Nivolumab or Nivolumab Plus Ipilimumab vs. Double Placebo for Stage IV Melanoma w. NED NCT02523313 | Prof. Dr. med. Dirk Schadendorf | Phase 2 |
| Unknown | GI Complications in Cancer Immunotherapy Patients NCT02784366 | Massachusetts General Hospital | — |
| Terminated | Complementary Vaccination With Dendritic Cells Pulsed With Autologous Tumor Lysate in Resected Stage III and I NCT02718391 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | Phase 2 |
| Unknown | Buparlisib in Melanoma Patients Suffering From Brain Metastases (BUMPER) NCT02452294 | University Hospital Tuebingen | Phase 2 |
| Completed | Tissue and Hematopoietic/Mesenchymal Stem Cell for Humanized Xenograft Studies in Melanoma and Squamous Head a NCT02331134 | University of Colorado, Denver | N/A |
| Completed | A Tissue Collection Study of Pembrolizumab (MK-3475) in Subjects With Resectable Advanced Melanoma NCT02434354 | Abramson Cancer Center at Penn Medicine | Phase 1 |
| Completed | Safety of UV1 Vaccination in Combination With Ipilimumab in Patients With Unresectable or Metastatic Malignant NCT02275416 | Ultimovacs ASA | Phase 1 / Phase 2 |
| Terminated | Neoadjuvant Vemurafenib + Cobimetinib + Atezolizumab in Melanoma: NEO-VC NCT02303951 | University Hospital Tuebingen | Phase 2 |
| Completed | Dabrafenib and Trametinib for BRAF-inhibitor Pretreated Patients NCT02296996 | Universitair Ziekenhuis Brussel | Phase 2 |
| Unknown | Biomarkers for the Activity of Immune Checkpoint Inhibitor Therapy in Patients With Advanced Melanoma NCT02673970 | Universitair Ziekenhuis Brussel | — |
| Completed | Comparison of PET/CT and Ultrasound in Staging of Malignant Melanoma NCT04253574 | University of Basel | — |
| Completed | An Observational Study of BRAF Inhibitors Effectiveness in Patients With Newly Diagnosed Metastatic Melanoma NCT02143999 | Hoffmann-La Roche | — |
| Completed | A Study of Combination Treatment With HF10 and Ipilimumab in Patients With Unresectable or Metastatic Melanoma NCT02272855 | Takara Bio Inc. | Phase 2 |
| Completed | Fluorescence Imaging in Sentinel Lymph Node Biopsy for Breast Cancer and Melanoma NCT02316795 | Washington University School of Medicine | EARLY_Phase 1 |
| Active Not Recruiting | A National Phase IV Study With Ipilimumab for Patients With Advanced Malignant Melanoma. NCT02068196 | Oslo University Hospital | Phase 4 |
| Completed | Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With NCT01962103 | Celgene | Phase 1 / Phase 2 |
| Terminated | A Phase II Study of Vemurafenib Combined With Acitretin in Patients With Advanced Melanoma NCT02050321 | University of Arizona | Phase 2 |
| Completed | An Open-Label Study of Zelboraf (Vemurafenib) in Patients With Braf V600 Mutation Positive Metastatic Melanoma NCT01898585 | Hoffmann-La Roche | Phase 4 |
| Completed | A Study of Vemurafenib (Zelboraf) in Chinese Participants With BRAF V600 Mutation-Positive Unresectable or Met NCT01910181 | Hoffmann-La Roche | Phase 1 |
| Recruiting | Modified Vaccine for High Risk or Low Residual Melanoma Patients NCT01898039 | Hadassah Medical Organization | Phase 1 / Phase 2 |
| Completed | An Observational Safety Study in Zelboraf (Vemurafenib)-Treated Patients With BRAF-V600 Mutation-Positive Unre NCT01990248 | Hoffmann-La Roche | — |
| Recruiting | Follow-up of a National Cohort of Melanoma Resectable Stage II, Stage III or IV Patients or Unresectable Prima NCT02828202 | Assistance Publique - Hôpitaux de Paris | — |
| Completed | A Study Comparing Vemurafenib Versus Vemurafenib Plus Cobimetinib in Participants With Metastatic Melanoma NCT01689519 | Hoffmann-La Roche | Phase 3 |
| Terminated | BRIM-P: A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 M NCT01519323 | Hoffmann-La Roche | Phase 1 |
| Terminated | A Study of Pegylated Interferon Alfa-2b (MK-4031) as an Adjuvant Treatment in Japanese Patients With Malignant NCT01636960 | Merck Sharp & Dohme LLC | Phase 1 |
| Completed | Comparison of In-House Methods and Cobas BRAF V600 Mutation Assay in Melanoma Tumor Samples NCT01744860 | Hoffmann-La Roche | — |
| Completed | Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Participants With Advanced Melanoma (MK-3475-002/P0871 NCT01704287 | Merck Sharp & Dohme LLC | Phase 2 |
| Terminated | Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreate NCT01696045 | Bristol-Myers Squibb | Phase 2 |
| Completed | A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participan NCT01656642 | Genentech, Inc. | Phase 1 |
| Terminated | Peptide Vaccine and Temozolomide for Metastatic Melanoma Patients NCT01543464 | Inge Marie Svane | Phase 2 |
| Completed | A Study of DEDN6526A in Patients With Metastatic or Unresectable Melanoma NCT01522664 | Genentech, Inc. | Phase 1 |
| Unknown | Anesthesia and Cancer Recurrence im Malignant Melanoma NCT01588847 | University Hospital Muenster | N/A |
| Completed | A Phase II Study to Evaluate Safety and Efficacy of Combined Treatment With Ipilimumab and Intratumoral Interl NCT01480323 | University Hospital Tuebingen | Phase 2 |
| Terminated | A Long Term Follow up Study for Patients Who Previously Took Part in the Phase I Study IMM-101-001 NCT01559818 | Immodulon Therapeutics Ltd | Phase 1 / Phase 2 |
| Completed | A Study of Intratumoral CAVATAK™ in Patients With Stage IIIc and Stage IV Malignant Melanoma (VLA-007 CALM ) NCT01227551 | Viralytics | Phase 2 |
| Completed | Study of the Anti-Angiogenesis Agent Axitinib in Patients With Stage III Malignant Melanoma NCT01321437 | University of California, Irvine | Phase 2 |
| Completed | Safety, Tolerability and Efficacy Study of the Monoclonal Antibody, CT-011, in Patients With Metastatic Melano NCT01435369 | Medivation, Inc. | Phase 2 |
| Terminated | Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Mela NCT01586195 | Genentech, Inc. | Phase 2 |
| Completed | Phase I/IIa AdCD40L Immunogene Therapy for Malignant Melanoma and Other Solid Tumors NCT01455259 | Uppsala University | Phase 1 / Phase 2 |
| Completed | A Study to Evaluate the Efficacy of Docetaxel and Carboplatin in Metastatic Malignant Melanoma Failed First-Li NCT02223884 | Yonsei University | Phase 2 |
| Completed | A Study of Vemurafenib in Metastatic Melanoma Participants With Brain Metastases NCT01378975 | Hoffmann-La Roche | Phase 2 |
| Completed | A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab NCT01307267 | Pfizer | Phase 1 |
| Terminated | Lapatinib in Stage IV Melanoma With ERBB4 Mutations NCT01264081 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Study of Radiotherapy Administered in Combination With Ipilimumab in Patients With Unresectable Stage III or S NCT01557114 | Gustave Roussy, Cancer Campus, Grand Paris | Phase 1 |
| Completed | A Study of Vemurafenib in Participants With Metastatic Melanoma NCT01307397 | Hoffmann-La Roche | Phase 3 |
| Completed | A Study of Vemurafenib and GDC-0973 (Cobimetinib) in Participants With BRAFV600E Mutation-Positive Metastatic NCT01271803 | Hoffmann-La Roche | Phase 1 |
| Completed | A Study of the Effect of Food on the Pharmacokinetics of Single Dose RO5185426 And the Safety And Efficacy of NCT01264380 | Hoffmann-La Roche | Phase 1 |
| Completed | A Study of RO5185426 in Patients With Metastatic Melanoma NCT01248936 | Hoffmann-La Roche | Phase 2 |
| Completed | A Study of RO5185426 in Previously Treated Melanoma Patients With Brain Metastases NCT01253564 | Hoffmann-La Roche | Phase 2 |
| Completed | Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma NCT01211262 | Immunocore Ltd | Phase 1 |
| Unknown | Early Diagnosis of Malignant Transformation of Pigmentary Skin Lesions NCT01167998 | Hadassah Medical Organization | — |
| Completed | A Pharmacokinetic and Metabolism Study of 14C-labeled RO5185426 on Patients With Metastatic Melanoma NCT01164891 | Hoffmann-La Roche | Phase 1 |
| Completed | An Open-Label, Dose-Escalation Study of IMC-20D7S In Participants With Malignant Melanoma NCT01137006 | Eli Lilly and Company | Phase 1 |
| Completed | A Pharmacokinetic/Pharmacodynamic Study of RO5185426 in Previously Treated Patients With Metastatic Melanoma NCT01107418 | Hoffmann-La Roche | Phase 1 |
| Terminated | Study of a DNA Immunotherapy to Treat Melanoma NCT01138410 | Scancell Ltd | Phase 1 / Phase 2 |
| Completed | High Dose Interleukin-2 Followed by Intermittent Low Dose Temozolomide in Patients With Melanoma NCT01124734 | Milton S. Hershey Medical Center | Phase 2 |
| Completed | Intratumoral Application of L19IL2 in Patients With Malignant Melanoma NCT01253096 | Philogen S.p.A. | Phase 2 |
| Completed | SciBase International Melanoma Pivotal Study NCT01077050 | SciBase AB | N/A |
| Completed | Panobinostat (LBH589) in Patients With Metastatic Melanoma NCT01065467 | Dana-Farber Cancer Institute | Phase 1 |
| Completed | IL-2 "SELECT" Tissue Collection Protocol in Patients With Advanced Melanoma NCT01288963 | Beth Israel Deaconess Medical Center | — |
| Completed | A Study of Vemurafenib (RO5185426) in Comparison With Dacarbazine in Previously Untreated Patients With Metast NCT01006980 | Hoffmann-La Roche | Phase 3 |
| Completed | Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage NCT01024231 | Bristol-Myers Squibb | Phase 1 |
| Withdrawn | Evaluation of Interferon-Lovastatin Therapy for Malignant Melanoma NCT00963664 | NeoPlas Innovation | Phase 2 |
| Completed | A Pharmacokinetic Study of RO5185426 in Combination With a Drug Cocktail in Patients With Metastatic Melanoma NCT01001299 | Hoffmann-La Roche | Phase 1 |
| Unknown | SentoClone® Compared to Reference Treatment in Advanced Malignant Melanoma NCT00991250 | SentoClone AB | Phase 2 |
| Completed | A Study of Vemurafenib in Previously Treated Patients With Metastatic Melanoma NCT00949702 | Hoffmann-La Roche | Phase 2 |
| Completed | Transfected Dendritic Cell Based Therapy for Patients With Breast Cancer or Malignant Melanoma NCT00978913 | Inge Marie Svane | Phase 1 |
| Completed | Study of HF10 in Patients With Refractory Head and Neck Cancer or Solid Tumors With Cutaneous and/or Superfici NCT01017185 | Takara Bio Inc. | Phase 1 |
| Completed | A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma NCT00864253 | Celgene | Phase 3 |
| Unknown | Quality of Life and Psychological Well-being in Patients With Malignant Melanoma NCT00963261 | University Hospital Freiburg | N/A |
| Completed | Activated Allogeneic Lymphocytes for Induction Graft Versus Tumor Effect in Metastatic Solid Tumors NCT00855452 | Hadassah Medical Organization | Phase 2 |
| Completed | Comparison of Video-Based Versus Written Patient Education on Melanoma NCT00826995 | University of California, Davis | N/A |
| Unknown | The Identification of Novel Prognostic Markers in Melanoma NCT01002560 | Royal Marsden NHS Foundation Trust | — |
| Completed | Study to Assess the Effect of Dosing AZD6244 HydSulfate in the Presence and Absence of Food in Patients With A NCT00710515 | AstraZeneca | Phase 1 |
| Completed | Immunohistochemical Expression Patterns of microRNA Processing Enzyme Dicer in Cutaneous Malignant Melanoma, B NCT00862914 | Ruhr University of Bochum | — |
| Completed | Combination of Decitabine and Temozolomide in the Treatment of Patients With Metastatic Melanoma NCT00715793 | Hussein Tawbi | Phase 1 / Phase 2 |
| Active Not Recruiting | Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma NCT00539591 | St. Jude Children's Research Hospital | Phase 2 |
| Completed | Safety and Immunogenicity of CYT004-MelQbG10 Vaccine With and Without Adjuvant in Advanced Stage Melanoma Pati NCT00651703 | Cytos Biotechnology AG | Phase 2 |
| Terminated | Effect of rIL-21 on Metastases in Lymph Nodes in Melanoma Skin Cancer NCT00601861 | Novo Nordisk A/S | Phase 2 |
| Completed | In Vitro Expanded Autologous Invariant Natural Killer Cells in Cancer NCT00631072 | Beth Israel Deaconess Medical Center | Phase 1 |
| Terminated | Chemotherapy Followed by Infusion of DMF5 Cells to Treat Metastatic Melanoma NCT00924001 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Phase II Study of Short-Term Cultured Anti-Tumor Autologous Lymphocytes After Lymphocyte-Depleting Chemotherap NCT00513604 | National Cancer Institute (NCI) | Phase 2 |
| Completed | A Phase II Trial OF Carboplatin, ABI-007 (Abraxane) And Sorafenib (BAY 43-9006) in Metastatic Melanoma NCT00483301 | Mt. Sinai Medical Center, Miami | Phase 2 |
| Completed | Vaccination With Tumor mRNA in Metastatic Melanoma - Fixed Combination Versus Individual Selection of Targeted NCT00204516 | University Hospital Tuebingen | Phase 1 / Phase 2 |
| Completed | Multicentre, Dose Finding, Ph II,CP-4055 in Comb. With Sorafenib - Patients With Metastatic Malignant Melanoma NCT00498836 | Clavis Pharma | Phase 2 |
| Completed | A Study of Avastin (Bevacizumab) in Combination With Fotemustine in Patients With Metastatic Melanoma NCT01069627 | Hoffmann-La Roche | Phase 2 |
| Completed | Safety Study of PLX4032 in Patients With Solid Tumors NCT00405587 | Plexxikon | Phase 1 |
| Completed | A Study of MDX-1106 in Patients With Selected Refractory or Relapsed Malignancies NCT00441337 | Bristol-Myers Squibb | Phase 1 |
| Completed | Sentinel Node With Ultrasound Contrast in Melanoma NCT00370136 | Rigshospitalet, Denmark | N/A |
| Completed | A Study of Bevacizumab (Avastin) in Combination With Dacarbazine in Participants With Unresectable/Metastatic NCT01164007 | Hoffmann-La Roche | Phase 2 |
| Completed | Phase II Trial of Ontak With Metastatic Melanoma NCT00299689 | James Graham Brown Cancer Center | Phase 2 |
| Completed | Vaccine Treatment for Advanced Malignant Melanoma NCT00300612 | NewLink Genetics Corporation | Phase 1 / Phase 2 |
| Completed | Phase II Trial of (IL-2) With Priming and (GM-CSF) in Patients With Advanced Melanoma NCT00616564 | Mt. Sinai Medical Center, Miami | Phase 2 |
| Completed | International Melanoma Algorithm Training Study - IMATS NCT00966173 | SciBase AB | N/A |
| Completed | A Study of MDX-010 (BMS-734016) Administered With or Without Prophylactic Oral Budesonide NCT00135408 | Bristol-Myers Squibb | Phase 2 |
| Completed | Intratumoural Administration of Coxsackievirus A21 for the Control of Malignant Melanoma (PXS-X02) NCT00235482 | Viralytics | Phase 1 |
| Terminated | FR901228 in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma NCT00104884 | ECOG-ACRIN Cancer Research Group | Phase 2 |
| Completed | Local Treatment of Metastatic Melanoma With Autologous Lymphocytes and the Bispecific Antibody rM28 NCT00204594 | University Hospital Tuebingen | Phase 1 / Phase 2 |
| Completed | Study of the Combination of Lenalidomide and DTIC (Dacarbazine) in Patients With Metastatic Malignant Melanoma NCT00179608 | Celgene | Phase 1 |
| Completed | Clinical Study of Previously Untreated Patients With Malignant Melanoma NCT00232726 | Clavis Pharma | Phase 2 |
| Completed | NY-ESO-1 Protein Vaccine With Imiquimod in Melanoma (Adjuvant Setting) NCT00142454 | Ludwig Institute for Cancer Research | Phase 1 |
| Unknown | IVIG in the Treatment of Metastatic Cancers of the Prostate, Colon and Melanoma NCT00294476 | GammaCan | Phase 2 |
| Completed | Safety and Efficacy Trial of Imexon Plus DTIC in Advanced Malignant Melanoma NCT00327600 | AmpliMed Corporation | Phase 1 / Phase 2 |
| Completed | Study of the Tumor Saturation and Biological Activity of MEDI-522 (Abergrin) in Patients With Advanced Maligna NCT00111696 | MedImmune LLC | Phase 1 |
| Unknown | Safety and Efficacy Study of INGN 241 Gene Therapy in Patients With In Transit Melanoma NCT00116363 | Introgen Therapeutics | Phase 2 |
| Terminated | Phase I/II Trial of Valproic Acid and Karenitecin for Melanoma NCT00358319 | H. Lee Moffitt Cancer Center and Research Institute | Phase 1 / Phase 2 |
| Completed | Pharmacokinetic Study of Liposomal Vincristine in Patients With Malignant Melanoma & Hepatic Dysfunction NCT00145041 | Acrotech Biopharma Inc. | Phase 1 |
| Terminated | Immunization With the MAGE-3.A1 Peptide Mixed With the Adjuvant CpG 7909 in Patients With Metastatic Melanoma NCT00145145 | Ludwig Institute for Cancer Research | Phase 1 / Phase 2 |
| Terminated | Immunization With 8 Peptides Mixed With CpG 7909 or Montanide ISA51 in Patients With Metastatic Cutaneous Mela NCT00145158 | Ludwig Institute for Cancer Research | Phase 1 / Phase 2 |
| Completed | Trial With Telomerase Peptide Vaccine In Combination With Temozolomide in Patients With Advanced Malignant Mel NCT01247623 | Oslo University Hospital | Phase 1 / Phase 2 |
| Completed | GM-CSF as Adjuvant Therapy of Melanoma NCT00350597 | Northern California Melanoma Center | Phase 2 |
| Completed | Efficacy Study of IL-21 to Treat Metastatic Melanoma NCT00336986 | Novo Nordisk A/S | Phase 2 |
| Completed | Intradermal Vaccination With Stabilized Tumor mRNA - a Clinical Phase I/II Trial in Melanoma Patients NCT00204607 | University Hospital Tuebingen | Phase 1 / Phase 2 |
| Completed | Phase I Trial of Intratumoral pIL-12 Electroporation in Malignant Melanoma NCT00323206 | H. Lee Moffitt Cancer Center and Research Institute | N/A |
| Terminated | A Pilot Study of Pivanex in Patients With Malignant Melanoma NCT00087477 | Titan Pharmaceuticals | Phase 1 / Phase 2 |
| Completed | A Study of Continued Treatment Among Participants Who Have Responded to Peginterferon Alfa-2a (Pegasys®) or Re NCT02829775 | Hoffmann-La Roche | Phase 2 / Phase 3 |
| Completed | CP-675,206 In Patients With Advanced Melanoma NCT00086489 | AstraZeneca | Phase 2 |
| Completed | Study of MDX-010 in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma NCT00729950 | Bristol-Myers Squibb | Phase 1 |
| Unknown | Survivin Peptide Vaccination for Patients With Advanced Melanoma, Pancreatic, Colon and Cervical Cancer NCT00108875 | Julius-Maximilians University | Phase 1 / Phase 2 |
| Completed | Post-Operative Drainage Following Lymph Node Dissection NCT00324272 | Oxford University Hospitals NHS Trust | Phase 4 |
| Terminated | CP-461 in the Treatment of Patients With Advanced Melanoma NCT00060710 | Astellas Pharma Inc | Phase 2 |
| Completed | A Survey Study to See if Patients Diagnosed With Parkinson's Disease Have Higher Incidence of Melanoma NCT00203008 | Teva Branded Pharmaceutical Products R&D, Inc. | — |
| Terminated | Study of Taxoprexin Injection vs. Dacarbazine in Patients With Metastatic Malignant Melanoma NCT00087776 | American Regent, Inc. | Phase 3 |
| Completed | Thymosin Alpha 1, Interferon Alpha, or Both, in Combination With Dacarbazine in Patients With Malignant Melano NCT00911443 | sigma-tau i.f.r. S.p.A. | Phase 2 |
| Completed | Fotemustine and Dacarbazine Versus Dacarbazine +/- Alpha Interferon in Advanced Malignant Melanoma NCT01359956 | National Cancer Institute, Naples | Phase 3 |
| Completed | Study of gp75 Vaccine in Patients With Stage III and IV Melanoma NCT00034554 | Eli Lilly and Company | Phase 1 |
| Completed | Trial of Vaccine Therapy With mRNA- Transfected Dendritic Cells in Patients With Advanced Malignant Melanoma NCT01278940 | Oslo University Hospital | Phase 1 / Phase 2 |
| Completed | Immediate Radiotherapy or Observation After Surgery for Melanoma Involving Lymph Nodes NCT00287196 | Trans Tasman Radiation Oncology Group | Phase 3 |
| Completed | Study of Heat Shock Protein-Peptide Complex (HSPPC-96) Versus IL-2/DTIC for Stage IV Melanoma NCT00039000 | Agenus Inc. | Phase 3 |
| Completed | Phase II Trial of Allovectin-7® for Metastatic Melanoma NCT00044356 | Vical | Phase 2 |
| Completed | Immunoablative Mini Transplant (Hematopoietic Peripheral Blood Stem Cell Transplant [HPBSC]) NCT00179764 | Ann & Robert H Lurie Children's Hospital of Chicago | N/A |
| Completed | Optical Biopsy of Human Skin in Conjunction With Laser Treatment NCT00540566 | University of California, Irvine | — |
| Completed | Safety and Immunogenicity of a Melan-A VLP Vaccine in Early Stage Melanoma Patients NCT00306566 | Cytos Biotechnology AG | Phase 1 / Phase 2 |
| Unknown | Vaccine Therapy for Patients With Stage III Melanoma NCT00052130 | CancerVax Corporation | Phase 3 |
| Completed | Safety and Immunogenicity of a Melan-A VLP Vaccine in Advanced Stage Melanoma Patients NCT00306553 | Cytos Biotechnology AG | Phase 2 |
| Withdrawn | Study of Two Dose Levels of RTA 402 in Patients With Advanced Malignant Melanoma NCT00535314 | Biogen | Phase 2 |
| Unknown | Vaccine Therapy for Patients With Stage IV Melanoma NCT00052156 | CancerVax Corporation | Phase 3 |
| Terminated | A Safety and Efficacy Study of Intravenous 131I-TM601 in Adult Patients With Malignant Melanoma NCT00733798 | TransMolecular | Phase 1 / Phase 2 |
| No Longer Available | Expanded Access Program With Nivolumab in Combination With Ipilimumab in Patients With Tumors Unable to be Rem NCT02186249 | Bristol-Myers Squibb | — |